Breast Cancer

The administration of the CDK4/6 inhibitor trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

December 10, 2020 - Patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay, showed a trend for greater benefit with adjuvant pertuzumab therapy, according to an exploratory analysis of the data from the APHINITY trial.

December 10, 2020 - Treatment with abemaciclib in combination with endocrine therapy significantly reduced the risk of invasive disease recurrence or death in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who had high Ki-67 tumors, suggesting that this feature can be used in conjunction with high-risk features to select patients for abemaciclib in the adjuvant setting.

December 10, 2020 — Oral paclitaxel and encequidar elicited lower rates of chemotherapy-induced peripheral neuropathy, as well as greater efficacy, in patients with metastatic breast cancer compared to intravenous paclitaxel.

December 10, 2020 - Mindfulness meditation and survivorship education classes reduced depressive symptoms in younger women treated for breast cancer.

December 10, 2020 - Fam-trastuzumab deruxtecan-nxki continued to showcase impressive signals of efficacy, including prolonged, durable responses and overall survival rates, as well as a tolerable safety profile in patients with HER2-positive metastatic breast cancer.

December 10, 2020 — The addition of ribociclib to endocrine therapy continued to significantly improve overall survival and delay subsequent chemotherapy compared with placebo, irrespective of endocrine partner in patients with hormone receptor–positive, HER2-negative breast cancer.

December 9, 2020 - Treatment with tamoxifen versus anastrozole did not yield any significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ but understanding associated toxicities can inform care decisions.

December 9, 2020 - Whole breast irradiation, following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

Ian Kunkler, FRCP, FRCR, DMRT, MRCP, discusses the 10-year results of the PRIME 2 trial in patients with breast cancer

December 9, 2020 - The combination of oral paclitaxel and encequidar led to an estimated 26.5% reduction in the risk of death compared with intravenous paclitaxel in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.

Kevin Kalinsky, MD, MS, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor–positive, HER2-negative breast cancer.

December 9, 2020 - The artificial intelligence–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

December 9, 2020 - Intrinsic tumor subtype was found to be associated with prognosis in patients with hormone receptor–positive, HER2-negative advance breast cancer who received the CDK4/6 inhibitor ribociclib.

December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.

December 9, 2020 - Follow-up circulating tumor cell assessments were confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer, when performed at a median of 29 days following treatment initiation.

December 8, 2020 - Oncologists widely under-recognize substantial symptoms in patients with breast cancer receiving radiotherapy after undergoing a lumpectomy, highlighting a need to improve symptom detection.

The addition of chemotherapy to endocrine therapy led to an improvement in 5-year invasive disease-free survival and overall survival in premenopausal but not postmenopausal women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center – Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London.

Hope S. Rugo, MD, discusses the significance of becoming a Giant of Cancer Care®.

Debra Patt, MD, PhD, MBA, ​breast medical oncologist​, vice president of Texas Oncology, highlight​s the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Cynthia X. Ma, MD, PhD, discusses several research efforts examining mechanisms of resistance to CDK4/6 and PI3K inhibitors in breast cancer and some of the novel combinations that may possess the potential to overcome this challenge.

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.